Synthetic vaccine update: Applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization

Adriana Bermúdez, Claudia Reyes, Fanny Guzmán, Magnolia Vanegas, Jaiver Rosas, Roberto Amador, Raul Rodríguez, Manuel Alfonso Patarroyo, Manuel Elkin Patarroyo

Resultado de la investigación: Contribución a RevistaArtículo

15 Citas (Scopus)

Resumen

The SPf66 synthetic malaria vaccine, developed and obtained almost 2 decades ago, represents the first approach towards developing a multi-antigenic, multi-stage synthetic malarial vaccine composed of subunits derived from different Plasmodium falciparum stage proteins. It is shown here that batches 03, 04, 05, 06, 07, 08, 09, 10, 11, 12, 13, 14, 15 and 16 produced from a few milligrams to kilogram amounts and used in assays on monkeys and humans showed high reproducibility in physicochemical analysis. 1H NMR two-dimensional studies also revealed high similarity, even in non-oxidized batches. Reproducibility was also high, especially in preclinical studies carried out on Aotus, clinical trials Phase I, IIa and IIb and field-studies carried out in La Tola, Rio Rosario (Colombia), Majadas (Venezuela), La Te (Ecuador), Ifakara (Tanzania) in which there was high antibody titer production, having similar population distribution when done with different batches. These results provide great support for peptide-synthesized vaccines containing minimal epitopes from protection-inducing antigens which have several advantages, such as low cost, safety, reproducibility, stability, being straightforwardly scaled-up from milligram to kilogram amounts; make them the vaccines of choice for the future in a worldwide attempt to scourge diseases such as malaria. © 2007 Elsevier Ltd. All rights reserved.
Idioma originalEnglish (US)
Páginas (desde-hasta)4487-4501
Número de páginas15
PublicaciónVaccine
Volumen25
N.º22
DOI
EstadoPublished - may 30 2007
Publicado de forma externa

Huella dactilar

synthetic vaccines
Malaria Vaccines
Synthetic Vaccines
reproducibility
subunit vaccines
vaccines
Ecuador
Venezuela
Clinical Trials, Phase I
Subunit Vaccines
Colombia
Tanzania
Plasmodium falciparum
Malaria
Antibody Formation
Haplorhini
Aotus (Cebidae)
Epitopes
Vaccines
population distribution

Citar esto

Bermúdez, Adriana ; Reyes, Claudia ; Guzmán, Fanny ; Vanegas, Magnolia ; Rosas, Jaiver ; Amador, Roberto ; Rodríguez, Raul ; Patarroyo, Manuel Alfonso ; Patarroyo, Manuel Elkin. / Synthetic vaccine update: Applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization. En: Vaccine. 2007 ; Vol. 25, N.º 22. pp. 4487-4501.
@article{1449f3c83c23437eb632eb76482805ca,
title = "Synthetic vaccine update: Applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization",
abstract = "The SPf66 synthetic malaria vaccine, developed and obtained almost 2 decades ago, represents the first approach towards developing a multi-antigenic, multi-stage synthetic malarial vaccine composed of subunits derived from different Plasmodium falciparum stage proteins. It is shown here that batches 03, 04, 05, 06, 07, 08, 09, 10, 11, 12, 13, 14, 15 and 16 produced from a few milligrams to kilogram amounts and used in assays on monkeys and humans showed high reproducibility in physicochemical analysis. 1H NMR two-dimensional studies also revealed high similarity, even in non-oxidized batches. Reproducibility was also high, especially in preclinical studies carried out on Aotus, clinical trials Phase I, IIa and IIb and field-studies carried out in La Tola, Rio Rosario (Colombia), Majadas (Venezuela), La Te (Ecuador), Ifakara (Tanzania) in which there was high antibody titer production, having similar population distribution when done with different batches. These results provide great support for peptide-synthesized vaccines containing minimal epitopes from protection-inducing antigens which have several advantages, such as low cost, safety, reproducibility, stability, being straightforwardly scaled-up from milligram to kilogram amounts; make them the vaccines of choice for the future in a worldwide attempt to scourge diseases such as malaria. {\circledC} 2007 Elsevier Ltd. All rights reserved.",
author = "Adriana Berm{\'u}dez and Claudia Reyes and Fanny Guzm{\'a}n and Magnolia Vanegas and Jaiver Rosas and Roberto Amador and Raul Rodr{\'i}guez and Patarroyo, {Manuel Alfonso} and Patarroyo, {Manuel Elkin}",
year = "2007",
month = "5",
day = "30",
doi = "10.1016/j.vaccine.2007.03.016",
language = "English (US)",
volume = "25",
pages = "4487--4501",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "22",

}

Bermúdez, A, Reyes, C, Guzmán, F, Vanegas, M, Rosas, J, Amador, R, Rodríguez, R, Patarroyo, MA & Patarroyo, ME 2007, 'Synthetic vaccine update: Applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization', Vaccine, vol. 25, n.º 22, pp. 4487-4501. https://doi.org/10.1016/j.vaccine.2007.03.016

Synthetic vaccine update: Applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization. / Bermúdez, Adriana; Reyes, Claudia; Guzmán, Fanny; Vanegas, Magnolia; Rosas, Jaiver; Amador, Roberto; Rodríguez, Raul; Patarroyo, Manuel Alfonso; Patarroyo, Manuel Elkin.

En: Vaccine, Vol. 25, N.º 22, 30.05.2007, p. 4487-4501.

Resultado de la investigación: Contribución a RevistaArtículo

TY - JOUR

T1 - Synthetic vaccine update: Applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization

AU - Bermúdez, Adriana

AU - Reyes, Claudia

AU - Guzmán, Fanny

AU - Vanegas, Magnolia

AU - Rosas, Jaiver

AU - Amador, Roberto

AU - Rodríguez, Raul

AU - Patarroyo, Manuel Alfonso

AU - Patarroyo, Manuel Elkin

PY - 2007/5/30

Y1 - 2007/5/30

N2 - The SPf66 synthetic malaria vaccine, developed and obtained almost 2 decades ago, represents the first approach towards developing a multi-antigenic, multi-stage synthetic malarial vaccine composed of subunits derived from different Plasmodium falciparum stage proteins. It is shown here that batches 03, 04, 05, 06, 07, 08, 09, 10, 11, 12, 13, 14, 15 and 16 produced from a few milligrams to kilogram amounts and used in assays on monkeys and humans showed high reproducibility in physicochemical analysis. 1H NMR two-dimensional studies also revealed high similarity, even in non-oxidized batches. Reproducibility was also high, especially in preclinical studies carried out on Aotus, clinical trials Phase I, IIa and IIb and field-studies carried out in La Tola, Rio Rosario (Colombia), Majadas (Venezuela), La Te (Ecuador), Ifakara (Tanzania) in which there was high antibody titer production, having similar population distribution when done with different batches. These results provide great support for peptide-synthesized vaccines containing minimal epitopes from protection-inducing antigens which have several advantages, such as low cost, safety, reproducibility, stability, being straightforwardly scaled-up from milligram to kilogram amounts; make them the vaccines of choice for the future in a worldwide attempt to scourge diseases such as malaria. © 2007 Elsevier Ltd. All rights reserved.

AB - The SPf66 synthetic malaria vaccine, developed and obtained almost 2 decades ago, represents the first approach towards developing a multi-antigenic, multi-stage synthetic malarial vaccine composed of subunits derived from different Plasmodium falciparum stage proteins. It is shown here that batches 03, 04, 05, 06, 07, 08, 09, 10, 11, 12, 13, 14, 15 and 16 produced from a few milligrams to kilogram amounts and used in assays on monkeys and humans showed high reproducibility in physicochemical analysis. 1H NMR two-dimensional studies also revealed high similarity, even in non-oxidized batches. Reproducibility was also high, especially in preclinical studies carried out on Aotus, clinical trials Phase I, IIa and IIb and field-studies carried out in La Tola, Rio Rosario (Colombia), Majadas (Venezuela), La Te (Ecuador), Ifakara (Tanzania) in which there was high antibody titer production, having similar population distribution when done with different batches. These results provide great support for peptide-synthesized vaccines containing minimal epitopes from protection-inducing antigens which have several advantages, such as low cost, safety, reproducibility, stability, being straightforwardly scaled-up from milligram to kilogram amounts; make them the vaccines of choice for the future in a worldwide attempt to scourge diseases such as malaria. © 2007 Elsevier Ltd. All rights reserved.

U2 - 10.1016/j.vaccine.2007.03.016

DO - 10.1016/j.vaccine.2007.03.016

M3 - Article

C2 - 17403557

VL - 25

SP - 4487

EP - 4501

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 22

ER -